Use of Stents and GP IIb/IIIa Inhibitors in PTCA Cases in American Hospitals

The HCIA-Sachs Institute presents the second study in its 100 Top Hospitals™ Clinical Research Program, Use of Stents and GP IIb/IIIa Inhibitors in PTCA Cases in American Hospitals: Benchmarks and Norms. This report focuses on the treatment of coronary heart disease, particularly with the addition of stents and a new class of drugs, glycoprotein IIb/IIIa inhibitors.

View lists of participating hospitals: 2000 | Previous

Read highlights of the study, including select noteworthy findings and methodology.

Participating hospitals can gain access to exclusive online benefits.

For more information about the 100 Top Hospitals™ Clinical Research Program, send e-mail to Dave Foster at dfoster@solucient.com or call him at (734) 669-7982.

Home > Studies > Clinical Research > Use of Stents